BioSpace News Archive

C4X entered into a licensing deal with AstraZeneca to develop an oral treatment for COPD and other inflammatory and respiratory illnesses that could reach $402 million.

Many executives haven’t established their personal brands or even know that they need one. BioSpace spoke with top executives in the field to learn about the importance of a personal executive brand.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark” or the “Company”) (an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the “Warrants”) issued in relation to a private placement financing that closed on December 13, 2019 on a continuing effort to improve corporate value for its shareholders.

Amentum has been awarded a $126 million, five-year contract by the U.S. Air Force for the Defense Technical Information Center (DTIC)

NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its PainShield® MD PLUS, its dual-actuator ultrasound pain therapy device.

Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today announced that the United States Patent and Trademark Office (“USPTO”) granted a patent (U.S. Patent No. 11,504,380) that protects the use of lanifibranor for the treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage.

Kala Pharmaceuticals, Inc. announced that it has entered into a definitive agreement with a life sciences-focused investor for the sale, in a private placement priced at-the-market under Nasdaq rules, of shares of its common stock and Series E Convertible Non-Redeemable Preferred Stock in two tranches for gross proceeds of up to $31 million.

DURECT Corporation announced that DURECT’s board of directors determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022.

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (“CNS”) disorders, today announced that it has postponed its Special Stockholder Meeting (the “Special Meeting”) originally scheduled for November 29, 2022 to allow additional time for stockholder voting proxies (the “Notice”).

Cambridge Cognition and Luca Healthcare announces a strategic partnership and a 10-year exclusive licensing agreement to commercialize Cambridge Cognition’s suite of cognitive assessment tools in the China market.